When the COVID-19 pandemic hit, the innovative pharmaceutical industry came together with the broader global health community and responded with unprecedented speed and scale, overcoming major hurdles along the way.
IFPMA reacted equally rapidly to the challenge of keeping the global public informed about our members’ actions.
In March 2020, our industry made seven commitments to communicate, guide, and measure its work in the fight against COVID-19.
Once the first vaccines were approved and manufacturing scale up had begun, IFPMA members committed to five steps to advance vaccine equity in May 2021. In February 2022, our members continued to draw attention to equity and announced three priorities to urgently increase access to COVID-19 vaccines.
vaccine doses have been administered1
vaccines have been granted Emergency Use Listing (EUL) by WHO
people remain unvaccinated in lower-income countries2
A rapid response
Since the pandemic began, the industry has overcome many obstacles while concentrating on rapidly deploying clinical trials, introducing new and repurposed treatments, and developing and rolling out new vaccines on groundbreaking technological platforms.
Today, more than 15 billion COVID-19 vaccines have been produced worldwide, facilitated by over 381 partnerships, voluntary licenses, and technology transfers.
Over 36 treatments have been approved for emergency use or standard of care including antivirals, anti-inflammatories, and monoclonal antibodies. Companies developing COVID-19 treatments entered into over 150 collaborations to expand manufacturing capacity.
Almost 70% of the global population is now partially vaccinated.
Advancing equitable access to innovation
IFPMA is a founding partner of the ACT-Accelerator and is fully committed to the goal of the WHO’s COVAX Pillar to accelerate development, production, and equitable access to safe, effective, and affordable COVID-19 vaccines.
Almost 70% of the global population is now partially vaccinated. Despite this remarkable achievement, there’s still much to be done to achieve COVID-19 vaccine equity.
Treatments are another important tool to fight COVID-19. Our industry has tested existing treatments and developed new ones, including antivirals, anti-inflammatories and monoclonal antibodies. It has prioritized equitable access by implementing multiple strategies, including over 150 voluntary licenses and tiered pricing.
To intensify efforts to turn vaccines into vaccinations, in collaboration across key stakeholders, the industry announced a renewed commitment to three priorities to urgently increase access to COVID-19 vaccines in February 2022: country readiness, equitable distribution, and innovation.Read more
In May 2021, after the approval of multiple effective and safe vaccines and the manufacturing scale up was in full swing, IFPMA members committed to five steps to advance vaccine equity, from dose sharing and optimized production to calling for the removal of trade barriers, country readiness, and further innovation.Read more
Applying lessons learned from COVID-19
Alongside its work in tackling COVID-19, the industry began reflecting on lessons learned that can inform how we create a healthier, safer, more equitable world. The innovative pharmaceutical industry proposes to turn these lessons into strategic insights that will guide future efforts to build effective pandemic preparedness and response.
This culminated in the groundbreaking Berlin Declaration in which industry proposes a framework to improve the real-time delivery of vaccines, treatments and diagnostics for priority populations in lower-income countries for future global pandemics
Applying Lessons Learned from COVID-19 to Create a Healthier, Safer, More Equitable World
This report identifies 10 insights the biopharmaceutical industry has gathered so far as the world moves into the third year of the COVID-19 pandemic.
It took just 326 days from genome sequencing to an approved COVID-19 vaccine. Making sure scientists have rapid access to pathogen data is a prerequisite for meeting the #100DaysMission ambition to respond to future pandemics. #AlwaysInnovatingShare this
Decades of R&D underpinned the scientific response to COVID-19. Sustaining this innovation to develop the next wave of groundbreaking technologies will give us a head start in responding to future pandemics. #AlwaysInnovatingShare this
Sustained and bolstered R&D on known and emerging disease was a key factor in the rapid COVID-19 response and is the best possible way to address the next pandemic. #AlwaysInnovatingShare this
Partnerships between companies allowed rapid scale up of COVID-19 tools. Voluntary partnerships that build resilient global manufacturing networks are vital in responding to future pandemics. #AlwaysInnovatingShare this
The innovative pharmaceutical industry is committed to improving pandemic preparedness for the future. IFPMA is helping to lead the way.
Technology transfer sustainably builds R&D gaps, increase the availability of vaccines and medicines, and stimulates investment in key industrial areas.
The IFPMA COVID-19 Innovation Timeline
This pinpoints the pivotal moments of the pharmaceutical industry and our partners’ response to the global pandemic, so that we can hopefully be better prepared for what could come next.
- 1 As of 30th September 2022
- 2 As of 22nd May 2022